RxDoctor Payments Data

Scott Beard, MD

Gynecology · Artesia, NMNPI 1932105301

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $577 of the $848 with a category attached, or 68.0%. Applied Medical Resources Corporation accounts for 78.8% of it on its own, with 7 other manufacturers making up the rest. 2023 is the largest year on record at $668, more than ten times the $60 reported in 2019.

$848in general payments, 2019–2025

Across 14 payments — averaging $60.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Applied Medical Resources Corporation$668
  • Amgen$71
  • Axonics, Inc.$25
  • Astellas Pharma US Inc$22
  • Pfizer$17
  • Coloplast$15
  • plus $29 from 2 others

What the payments were for

  • Travel & lodging$57768%
  • Food & beverage$25430%
  • Education$172%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$9,158
Medicare patients
18
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$7,337
PremarinEstrogens, Conjugated14$5,751
Oxybutynin Chloride ErOxybutynin Chloride31$265
NitrofurantoinNitrofurantoin Macrocrystal21$168
Imipramine Hcl21$124
Triamcinolone Acetonide13$97
Cephalexin18$90
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$22$7,33711 claims
PfizerPremarin$17$5,75114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.

Other gynecology in Artesia

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →